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Objectives We investigated the temporal pattern and predictive value (alone and in combination) of 4 urinary biomarkers
(neutrophil gelatinase-associated lipocalin [NGAL], interleukin [IL]-18, liver fatty acid-binding protein [L-FABP],
and kidney injury molecule [KIM]-1) for cardiac surgery–associated acute kidney injury (AKI).
Background Serum creatinine (SCr) is a delayed marker for AKI after cardiopulmonary bypass (CPB). Rapidly detectable AKI
biomarkers could allow early intervention and improve outcomes.
Methods Data from 220 pediatric patients were analyzed. Urine samples were obtained before and at intervals after CPB
initiation. AKI was defined as a 50% increase in SCr from baseline within 48 h after CPB. The temporal pattern
of biomarker elevation was established, and biomarker elevations were correlated with AKI severity and clinical
outcomes. Biomarker predictive abilities were evaluated by area under the curve (AUC), net reclassification im-
provement, and integrated discrimination improvement.
Results AKI occurred in 27% of patients. Urine NGAL significantly increased in AKI patients at 2 h after CPB initiation.
IL-18 and L-FABP increased at 6 h, and KIM-1 increased at 12 h. Biomarker elevations were correlated with AKI
severity and clinical outcomes and improved AKI prediction above a clinical model. At 2 h, addition of NGAL in-
creased the AUC from 0.74 to 0.85 (p  0.0001). At 6 h, NGAL, IL-18, and L-FABP each improved the AUC from
0.72 to 0.91, 0.84, and 0.77, respectively (all p  0.05). The added predictive ability of the biomarkers was sup-
ported by net reclassification improvement and integrated discrimination improvement. Biomarker combinations
further improved AKI prediction.
Conclusions Urine NGAL, IL-18, L-FABP, and KIM-1 are sequential predictive biomarkers for AKI and are correlated with dis-
ease severity and clinical outcomes after pediatric CPB. These biomarkers, particularly in combination, may help
establish the timing of injury and allow earlier intervention in AKI. (J Am Coll Cardiol 2011;58:2301–9)
© 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.08.017Acute kidney injury (AKI) after cardiac surgery is associated
with adverse outcomes, including prolonged intensive care
and hospital stays, diminished quality of life, and increased
long-term mortality (1). AKI occurs frequently, complicat-
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accepted August 2, 2011.ing 30% to 40% of adult and pediatric cardiac surgeries
(2,3). Even mild degrees of post-operative AKI portend a
significant increase in mortality (4) and morbidity (5).
Episodes of AKI may also lead to the development of
chronic kidney disease (6).
See page 2310
AKI diagnosis has relied on a rise in serum creatinine
(SCr) concentration, a delayed and unreliable measure in the
acute setting (7). The failure of interventional trials to
attenuate AKI after cardiac surgery has been attributed in
part to delays in diagnosis. Recent studies have focused on
the discovery and validation of early biomarkers of AKI.
Initial studies have demonstrated that neutrophil gelatinase-
associated lipocalin (NGAL), interleukin (IL)-18, liver fatty
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and kidney injury molecule
(KIM)-1 are individually ele-
vated in the urine early after
ischemic AKI (2,8–10). Most
studies have focused on the per-
formance of only 1 of these bio-
markers to detect AKI before an
SCr rise. The aims of this study
were to: 1) evaluate the temporal
pattern of elevation in these 4
biomarkers after cardiac surgery;
and 2) determine their predictive
values, individually and in com-
bination, when added to a clini-
cal predictive model.
Methods
Study design. This study was
approved by the Institutional Re-
view Board of Cincinnati Chil-
dren’s Hospital Medical Center.
All patients 18 years of age
undergoing cardiac surgery with
cardiopulmonary bypass (CPB)
at our center between January
2004 and July 2007 were ap-
proached for study inclusion. Pa-
tients with severe pre-existing re-
nal insufficiency (SCr 2 times
age-adjusted normal range) were
excluded. Written informed con-
sent was obtained before enroll-
ment from the legal guardian of
ach patient, with assent from the patient when appropriate.
Urine samples for biomarker analysis were obtained
mmediately before and at 2, 6, 12, and 24 h after initiation
f CPB and stored in aliquots at –80°C. The SCr was
outinely measured at baseline (within 72 h before surgery),
mmediately after surgery, and at least daily in the post-
perative period.
The primary outcome was AKI development, defined as
50% increase in SCr from pre-operative baseline within
48 h of surgery Complexity of surgery was categorized
according to the Risk Adjustment for Congenital Heart
Surgery Score version 1 (RACHS-1) consensus-based scor-
ing system (11). Secondary outcomes included severity of
AKI based on the pediatric modified Risk, Injury, Failure,
Loss, and End-Stage Kidney Disease (pRIFLE) criteria
(12), duration of AKI, duration of mechanical ventilation,
hospital length of stay (LOS), and hospital mortality. We
determined pRIFLE by calculation of estimated creatinine
clearance (eCCl) using the modified Schwartz formula (13),
with “Risk” defined as eCCl decrease of 25% from baseline,
Abbreviations
and Acronyms
AKI  acute kidney injury
AUC  area under the
curve
CPB  cardiopulmonary
bypass
eCCl  estimated
creatinine clearance
ELISA  enzyme-linked
immunosorbent assay
IDI  integrated
discrimination improvement
IL  interleukin
KIM  kidney injury
molecule
L-FABP  liver fatty acid-
binding protein
LOS  length of stay
NGAL  neutrophil
gelatinase-associated
lipocalin
NRI  net reclassification
improvement
pRIFLE  pediatric
modified Risk, Injury,
Failure, Loss, and End-
Stage Kidney Disease
RACHS-1  Risk Adjustment
for Congenital Heart Surgery
Score version 1
ROC  receiver-operating
characteristic
SCr  serum creatinine“Injury” defined as eCCl decrease of 50%, and “Failure”defined as eCCl decrease of 75% or absolute value 35
ml/min/1.73 m2. Duration of AKI was defined as the
umber of days SCr was 50% above baseline. We used
osages of inotropic infusions to calculate an inotrope score
t 24 h after CPB to provide a quantified index of the
ost-operative hemodynamic state (14).
iomarker measurements. Laboratory investigators were
linded to clinical outcomes. Urine NGAL was assayed
sing a human-specific commercially available enzyme-
inked immunosorbent assay (ELISA, AntibodyShop,
rusbakken, Denmark) (15). Urine IL-18 and L-FABP
ere measured using commercially available ELISA kits
Medical & Biological Laboratories Co., Nagoya, Japan,
nd CMIC Co., Tokyo, Japan, respectively) per manufac-
urer’s instructions. The urine KIM-1 ELISA was con-
tructed using commercially available reagents (R & D
ystems, Inc., Minneapolis, Minnesota) as described previ-
usly (16).
tatistical methods. The analysis subset included patients
ho had measurement of all 4 biomarkers at baseline and at
minimum of 1 post-operative time point (n  220) to
permit comparisons of biomarkers. Statistical analysis was
performed using SAS version 9.2 (SAS Institute, Cary,
North Carolina) and R version 2.12.1 (R Development
Core Team, Vienna, Austria). Demographics, baseline
measurements, and clinical outcomes were compared be-
tween AKI and non-AKI patients using the nonparametric
Wilcoxon rank sum test (continuous variables) or chi-square
or Fisher exact tests (categorical variables) as appropriate.
At each time point, the median biomarker measurements
were compared between AKI and non-AKI patients and
among patients in different pRIFLE strata using the rank
transformation approach. Tukey-Kramer adjustment was
used to adjust for multiple comparisons at each time point,
and adjusted p values were reported. Spearman correlation
coefficients were calculated to assess the association between
biomarker concentrations at each time point and the clinical
parameters.
Univariable logistic regression was used to assess the
discriminative ability of biomarkers to predict AKI.
Receiver-operator characteristic (ROC) curves were gener-
ated for each biomarker at each time point. The areas under
the curve (AUC) were compared between biomarkers using
the methods developed by DeLong (17). In a secondary
analysis, patients with pRIFLE “F” or “I” were assigned as
“severe AKI,” and we examined the ability of the biomarkers
to predict severe AKI.
Multivariable logistic regression analyses were conducted
to assess predictors of AKI as well as the performance of the
predictive models while combining biomarkers with clinical
factors. In addition to biomarkers, potential predictor vari-
ables included age, sex, race, CPB duration, prior CPB,
RACHS-1 score, and post-operative inotrope score. A
parsimonious clinical model (containing clinical factors
only) was first determined using backward elimination. The
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bination to the clinical model. Improvements in the model
performance were evaluated by AUC, net reclassification
improvement (NRI), and integrated discrimination im-
provement (IDI). No risk categories were selected for the
calculation of NRI. R package Hmisc was used for the
calculation of NRI and IDI (18,19).
Results
Of the 391 patients enrolled, 220 (56%) were retained for
analysis. The 171 excluded patients were among the first
174 patients enrolled. Because their samples were also
used for assay optimization, insufficient volume remained
for KIM-1 or L-FABP testing. Retained and excluded
patients were similar in incidence of AKI (27% vs. 35%,
p  0.10) and mortality (0.4% vs. 2.3%, p  0.05). No
patient in either group needed dialysis. AKI occurred in
60 of the 220 patients. Retained patient characteristics
are shown in Table 1. SCr increased by a median of 78%
n AKI patients. Ninety-eight percent of AKI patients
Patient CharacteristicsTable 1 Patient Characteristics
Characteristic
No A
(n  1
Age, yrs 3.3 (0.5–
Male 84 (53)
White race 142 (89)
Prior surgery 76 (48)
Bypass time, min 92 (67–
Baseline SCr, mg/dl 0.4 (0.4–
Baseline eCCL, ml/min/1.73 dm2 81.8 (65.0
Baseline urine NGAL, ng/ml 8.5 (4.0–
Baseline urine IL-18, pg/ml 1.2 (0.0–
Baseline urine KIM-1, pg/ml 193.9 (83.8
Baseline urine L-FABP, ng/ml 7.3 (2.3–
% SCr change 0.0 (0.0–
Hospital stay, days 5 (3–7
Ventilator, days 1 (1–2
Inotrope score 0.0 (0.0–
Death 0 (0)
RACHS score
1 20 (13)
2 68 (43)
3 60 (38)
4 9 (6)
5 2 (1)
6 1 (1)
pRIFLE
R —
I —
F —
Duration of AKI, days —
Dialysis 0 (0)
Values are median (interquartile range) for continuous variables (with
p values from chi-square test or Fisher exact test). pRIFLE and duratio
AKI acute kidney injury; eCCl estimated creatinine clearance; IL
protein; NGAL  neutrophil gelatinase-associated lipocalin; pRIFLE  pediatr
RACHS  risk adjustment for congenital heart surgery score version 1; SCr ere diagnosed 1 day after surgery. Among AKI patients,
5% developed pRIFLE-R, 35% developed pRIFLE-I,
nd 20% developed pRIFLE-F.
Patients who developed AKI were younger and had lower
aseline SCr. CPB times were longer in AKI patients, and
KI patients had longer duration of mechanical ventilation
nd hospital LOS. Baseline urinary biomarker concentra-
ions were similar in AKI and non-AKI groups, with the
xception of urine NGAL.
emporal elevation of biomarkers. As shown in Figure 1,
the temporal trends for all 4 urine biomarkers in non-AKI
patients were consistently low. In AKI patients, each of the 4
urine biomarkers rose significantly at some time point after
CPB initiation. Significant differences between AKI and non-
AKI patients were first seen at 2 h for NGAL, at 6 h for IL-18
and L-FABP, and at 12 h for KIM-1 (Figs. 1A to 1D). Once
biomarkers were elevated, they each remained elevated in AKI
patients at subsequent time points (all p  0.0001).
Figure 2 demonstrates the temporal trend in each urinary
biomarker according to pRIFLE. With the exception of
AKI
(n  60) p Value
0.6 (0.4–1.8) 0.0001
26 (43) 0.23
52 (87) 0.67
24 (40) 0.32
113 (84–172) 0.003
0.3 (0.2–0.4) 0.0001
) 110.6 (84.0–144.6) 0.0001
16.0 (10.0–24.0) 0.0001
0.9 (0.0–10.0) 0.65
4) 211.5 (96.2–377.9) 0.43
10.6 (4.2–31.2) 0.34
77.5 (64.6–108.3) 0.0001
7 (5–14) 0.0001
2 (1–2) 0.0001
0.0 (0.0–7.1) 0.19
1 (2) 0.27
0.14
4 (7)
29 (48)
24 (40)
0 (0)
1 (2)
2 (3)
—
27 (45)
21 (35)
12 (20)
2 (2–3) —
0 (0) —
s from Wilcoxon rank sum test) or n (%) for categorical variables (with
I are reported for AKI patients only.
leukin; KIM kidney injury molecule; L-FABP liver fatty acid-bindingKI
60)
6.0)
127)
0.6)
–99.1
12.5)
8.1)
–301.
27.4)
25.0)
)
)
0.0)
p value
n of AK
 interic modified Risk, Injury, Failure, Loss, and End-Stage Kidney Disease;
serum creatinine.
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biomarker was seen with worsening AKI severity.
Associations between urine biomarkers and clinical
characteristics. Spearman correlation coefficients for each
biomarker at its earliest elevation (2-h NGAL, 6-h IL-18,
6-h L-FABP, and 12-h KIM-1) with clinical parameters
are summarized in Table 2. Urine NGAL at 2 h was
correlated with younger age, greater SCr change, longer
CPB time, higher RACHS-1 scores, longer hospital stay,
longer ventilation time, and longer duration of AKI. Urine
IL-18 at 6 h was correlated with younger age, greater SCr
change, longer hospital stay, and longer ventilation time,
but not CPB time, RACH-1 score, or duration of AKI.
Urine L-FABP at 6 h and KIM-1 at 12 h were correlated
with younger age, greater SCr change, longer CPB time,
igher RACHS-1 scores, longer hospital stay, longer ven-
ilation time, and longer duration of AKI.
To determine whether biomarkers were independently
orrelated with hospital LOS and ventilator days, we per-
Figure 1 Urine Biomarker Concentrations by AKI Status
Median and interquartile range are presented. *Statistically significant differences
(A) Urine neutrophil gelatinase-associated lipocalin (NGAL); (B) urine interleukin (I
molecule (KIM)-1. CPB  cardiopulmonary bypass.ormed Spearman partial correlation, adjusting for the effect vf age, CPB time, and RACHS-1 score. At 2 h, NGAL was
ndependently correlated with hospital LOS and ventilator
ays. At 6 h, L-FABP was independently correlated with
ospital LOS, and at 12 h, KIM-1 was independently
orrelated with ventilator days. IL-18 did not show signif-
cant independent correlation with these outcomes.
redictive ability of biomarkers. Figure 3 demonstrates
he progression of ROC curves for each biomarker at each
ime point, from univariable logistic regression analysis. At
h after CPB initiation, urine NGAL was the only
redictive biomarker of AKI with an AUC of 0.90, signif-
cantly higher than the AUC for any of the other 3
iomarkers (all p  0.0001) (Fig. 3A). At 6 h, urine
GAL, IL-18, and L-FABP were significant predictors of
KI, but NGAL still had the highest discrimination (all
 0.001) (Fig. 3B). At 12 h, all 4 biomarkers performed
ell, with AUC in the good to outstanding range, but urine
GAL exhibited the highest AUC (all p 0.04) (Fig. 3C).
t 24 h, the predictive value of all 4 biomarkers remained
0.0001) in medians between acute kidney injury (AKI) and non-AKI patients.
(C) urine liver fatty acid-binding protein (L-FABP); (D) urine kidney injury(p 
L)-18;ery good, with improvement in the AUC of KIM-1 to
e2305JACC Vol. 58, No. 22, 2011 Krawczeski et al.
November 22, 2011:2301–9 Urinary Kidney Injury Biomarkers After Cardiopulmonary Bypass0.80. At 24 h, NGAL remained significantly better than
L-FABP (p  0.0004) but was not significantly superior to
ither IL-18 (p  0.17) or KIM-1 (p  0.11) (Fig. 3D).
We then performed multivariable logistic regression
analyses for the prediction of AKI. Evaluating clinical
Figure 2 Urine Biomarker Concentrations by pRIFLE Categories
Median and interquartile range are presented. Medians were compared between p
categories. Statistically significant differences (p  0.05) in medians are denoted
f (I vs. R). (A) Urine NGAL; (B) urine IL-18; (C) urine L-FABP; (D) urine KIM-1. Abb
Spearman Correlation CoefficientsBetween Urina y Biomarker Concentrationsand Cli ical Characteristics a d Outcomes
Table 2
Sp arman Correlatio Coefficients
Between Urinary Biomarker Concentrations
and Clinical Characteristics and Outcomes
T  2 h T  6 h T  12 h
NGAL IL-18 L-FABP KIM-1
Age 0.21 0.18 0.24 0.29
% SCr change 0.55 0.34 0.33 0.26
CPB time 0.38 0.11* 0.33 0.14
Hospital LOS 0.44 0.18 0.37 0.28
Ventilator days 0.37 0.22 0.28 0.31
RACHS-1 score 0.24 0.003* 0.21 0.13
Duration of AKI† 0.50 0.09* 0.31 0.48
*Insignificant correlation coefficients. All other correlation coefficients are significant (p  0.05).
†For AKI patients only.
CPB  cardiopulmonary bypass; LOS length of stay; T  time; other abbreviations as in Table 1.factors alone, younger age and longer CPB time were
independent predictors for AKI. Each biomarker was
then added to the clinical model to assess improvement in
the predictive ability of the model (Table 3). At 2 h after
CPB initiation, adding urine NGAL to the clinical
model increased the AUC from 0.74 to 0.85 (p 
0.0001). At 6 h, urine NGAL, IL-18, and L-FABP each
improved the AUC from 0.72 to 0.91, 0.84, and 0.77,
respectively (all p  0.05). At 12 h, all the 4 biomarkers
improved the AUC, with urine IL-18 having the most
improvement, which was maintained at 24 h after CPB
initiation. The added predictive ability of the individual
biomarker to the clinical model was also supported by the
results of NRI and IDI (Table 3).
Next, in order to assess whether the combination of
NGAL with other biomarkers would further improve the
predictive ability, we evaluated the performance of the
predictive models by adding 1, 2, or 3 other biomarkers
(IL-18, L-FABP, KIM-1) to the reference model, includ-
ic modified Risk, Injury, Failure, Loss, and End-Stage Kidney Disease (pRIFLE)
ers: a (F vs. no AKI), b (I vs. no AKI), c (R vs. no AKI), d (F vs. R), e (F vs. I), and
ns as in Figure 1.ediatr
by lett
reviatioing age, CPB time, and NGAL as predictors. At 2 h after
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other biomarkers were included in the model. At other
time points, the significance (p  0.05) of each bio-
marker in the model, AUC improvement, NRI, and IDI
are summarized in Table 4. At the 6-h time point, the
combination of NGAL  IL-18 provided the best results in
terms of AUC improvement, NRI, and IDI. At 12 h, the
best predictive ability was obtained when all 4 biomarkers
were included. However, the more parsimonious combina-
Figure 3 Receiver-Operator Characteristic Curves for Prediction
(A) T  2 h; (B) T  6 h; (C) T  12 h; (D) T  24 h. AUC  area under the cur
Evaluation of the Performance of Predictive Models After Adding aTable 3 Evaluation of the Performance of Predictive Models Af
Model
T  2 h (n  208, 50 AKI) T  6 h (n  211,
AUC NRI IDI AUC NRI
Clinical model 0.74 — — 0.72 —
 NGAL 0.85* 0.87† 0.12† 0.91* 1.24†
 IL-18 0.74 0.14 0.007 0.84* 0.93†
 L-FABP 0.73 0.17 0.004 0.77* 0.61†
 KIM-1 0.74 0.03 0.004 0.73 0.33†
For NRI, results correspond to % improvement in the performance of the predictive model. For exam
*Compared with the clinical model, age  CPB time, statistically significant (p  0.05) improvement in
AUC  area under the curve; IDI  integrated discrimination improvement; NRI  net reclassificationtion of NGAL  IL-18  L-FABP provided comparable
results. Similarly, at the 24-h mark, the best combination was all
4 biomarkers, but the combination of NGAL IL-18KIM-1
provided comparable results and could be used as the best
combination.
Finally, we evaluated the patients with “severe AKI”
(pRIFLE-I and -F) to determine the ability of the biomark-
ers to predict severe AKI. Thirty-three patients were in this
group. Our results were very similar to the full AKI cohort
KI Using Urine Biomarkers at Time Intervals After CPB
time; other abbreviations as in Figure 1.
ry Biomarker to the Clinical Modeldding a Urinary Biomarker to the Clinical Model
I) TT  12 h (n  204, 54 AKI) TT  24 h (n  205, 56 AKI)
DI AUC NRI IDI AUC NRI IDI
0.72 — — 0.72 — —
7† 0.85* 1.03† 0.12† 0.82* 0.99† 0.09†
8† 0.86* 0.86† 0.25† 0.86* 0.84† 0.24†
1† 0.81* 0.69† 0.15† 0.79* 0.60† 0.12†
06 0.79* 0.44† 0.11† 0.84* 0.83† 0.19†
I 0.87means 87% improvement over the reference model (i.e., clinical model: age CPB time).of A
ve; T Urinater A
56 AK
I
—
0.2
0.1
0.1
0.0
ple, NR
AUC. †p  0.05.
improvement; other abbreviations as in Table 1.
GAL); o
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elevations.
Discussion
Our results confirm that urine NGAL, IL-18, L-FABP,
and KIM-1 are predictors of post-cardiac surgery AKI. To
our knowledge, the current study is the first to: 1) establish
a temporal pattern of biomarker elevation after CPB; and
2) demonstrate the utility of biomarker combinations for the
improved prediction of AKI beyond clinical models. These
findings could enhance the potential for appropriately timed
application of therapeutic interventions. Additionally, these
biomarkers offer severity and prognostic information at early
time points.
The etiology of AKI after CPB is multifactorial and
incompletely understood. Because many pathways are in-
volved, it is not surprising that combinations of biomarkers
with different properties may prove most predictive. In this
study, we found that a clinical model of age and CPB time
could predict AKI with reasonable certainty. The addition
of biomarkers, however, particularly in combination, signif-
icantly increased the predictive value of the model. Thus a
panel of strategically selected and rapidly testable biomark-
ers may prove optimal for early diagnosis and institution of
treatment.
We studied 4 biomarkers as candidates for a sequential
AKI panel. Urine IL-18, NGAL, L-FABP, and KIM-1 are
all up-regulated and released by the kidney tubules during
injury and are biological intermediates in the causal mech-
Summary of Biomarker Combinations in the Model: Significance, ATable 4 Summary of Biomarker Combinations in the Model: Sig
T  6 h
Combination Biomarker p < 0.05 AUC NRI IDI p
I NGAL Yes 0.013 0.64* 0.10*
IL-18 Yes
I NGAL Yes 0.019 0.22 0.02
L-FABP Yes
I NGAL Yes 0.007 0.48* 0.01
KIM-1 No
II NGAL Yes 0.009 0.60* 0.11*
IL-18 Yes
L-FABP No
II NGAL Yes 0.013 0.56* 0.10*
IL-18 Yes
KIM-1 No
II NGAL Yes 0.003 0.21 0.03
L-FABP Yes
KIM-1 No
III NGAL Yes 0.012 0.61* 0.12*
IL-18 Yes
L-FABP No
KIM-1 No
At 2 h, only NGAL was significant. For NRI, results correspond to % improvement in the performan
(i.e., age  CPB time  NGAL). *p  0.05.
AUC  improvement in AUC when compared with the reference model (age  CPB time  Nanisms of ischemia-reperfusion injury to the kidney. Thesebiomarkers are present at low concentrations pre-
operatively, and their levels increase by several-fold in
patients who develop kidney injury. IL-18, a mediator of
inflammation, is produced by proximal tubules, and is
activated by caspase-1 after AKI (20). It is more specific to
ischemic AKI and is not significantly affected by nephro-
toxins or chronic kidney disease. The gene for NGAL is
significantly up-regulated in the kidney after ischemic and
nephrotoxic injury, and the protein is over-expressed in
distal tubule cells (21). NGAL may play a primary role in
renal tubular survival and recovery and has been used
therapeutically in ischemia-reperfusion injury in animal
models (22). Recent studies using an NGAL reporter
mouse have established that the kidney is the primary source
of urinary NGAL in AKI (23). L-FABP is an inflammatory
proximal tubular protein that is up-regulated after a variety of
acute kidney injuries (9,24,25). KIM-1 is a transmembrane
protein that is over-expressed in de-differentiated proximal
tubule cells after ischemic or toxic injury (10,21–23).
We found that urine NGAL concentrations increased at
the earliest time point after CPB and were associated with
the highest predictive value. We do note that, in some
studies, NGAL has not performed as well (26). We hypoth-
esize that this may be related to the confounding disease
states (e.g., diabetes, lung disease, inflammation) that may
be more prevalent in adults and may affect NGAL concen-
trations. This further highlights the need for a comprehen-
sive “panel” of biomarkers, optimizing both sensitivity and
specificity. Notably, our results demonstrate that combina-
provement, NRI, and IDIance, AUC Improvement, NRI, and IDI
T  12 h T  24 h
AUC NRI IDI p < 0.05 AUC NRI IDI
0.056* 0.77* 0.21* Yes 0.069* 0.77* 0.21*
Yes
0.002 0.41* 0.09* Yes 0.005 0.34* 0.08*
Yes
0.012 0.41* 0.05* Yes 0.026 0.66* 0.12*
Yes
0.060* 0.95* 0.27* Yes 0.073* 0.93* 0.25*
Yes
Yes
0.058* 0.79* 0.24* No 0.084* 1.00* 0.27*
Yes
Yes
0.010 0.63* 0.10* No 0.045 0.84* 0.15*
Yes
Yes
0.064* 0.98* 0.28* No 0.089* 1.01* 0.29*
Yes
No
Yes
e predictive model. For example, NRI  0.64 means 64% improvement over the reference model
ther abbreviations as in Tables 1 and 3.UC Imnific
< 0.05
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
ce of thtions of biomarkers provide additional predictive value.
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pre-operative NGAL levels in patients who developed
post-CPB AKI. It is possible that some of our patients had
subclinical pre-operative AKI, which may have pre-disposed
them to development of AKI.
With the exception of IL-18 in the pRIFLE-F patients,
all biomarker concentrations increased in a stepwise fashion
with worsening kidney injury. It is unclear why IL-18 did
not increase in the same pattern in pRIFLE-F patients,
particularly because it has performed well in other studies
(8). It is possible that this is due to the small number of
RIFLE-F patients analyzed, but further evaluation in larger
studies is warranted.
The importance of determining the temporal sequence of
the biomarkers is underscored by the fact that the course of
experimental AKI proceeds in 4 phases: initiation, exten-
sion, maintenance, and recovery (27). The initiation phase is
the period during which initial exposure to the ischemic
insult occurs, intracellular adenosine triphosphate depletion
is profound, and generation of reactive oxygen molecules
and labile iron is initiated. Vasodilator, adenosine triphos-
phate donor, antioxidant, and iron chelation therapies may
be especially effective during this phase, and the appearance
of the earliest noninvasive biomarkers such as NGAL may
be used to trigger such therapies. Prolongation of ischemia
followed by reperfusion ushers in the extension phase.
Tubules undergo reperfusion-mediated cell death, and the
injured endothelial and epithelial cells amplify the inflam-
matory cascades. This phase probably represents a window
of opportunity for early diagnosis with intermediate bio-
markers such as L-FABP and IL-18 and active therapeutic
intervention with antiapoptotic and anti-inflammatory
strategies. During the maintenance phase, both cell injury
and regeneration occur simultaneously. Measures such as
growth factors and stem cells that accelerate the endogenous
regeneration processes, initiated by later biomarkers with
high specificity such as KIM-1, may be most effective
during this phase.
Study strengths and limitations. Our study has several
strengths. First, we used a prospective cohort design and a
rigorous protocol to collect specimens, followed by blinded
measurements of biomarkers. Second, we enrolled a large,
relatively homogenous cohort of subjects in whom the most
proximate etiology for AKI would be CPB. The study
design also allowed for the precise determination of the
temporal rise in biomarkers after CPB.
This study does have important limitations. First, this
remains a single-center study, which needs validation at the
multicenter level. Second, our results may not be general-
izable to adults undergoing CPB or to the myriad other
clinical scenarios that commonly lead to AKI in hospitalized
patients. Third, SCr levels were not measured at the same
requency as the urinary biomarkers examined, and the exact
iming of SCr rise in our study population is uncertain.
Fourth, the definition of AKI was based on elevations in
SCr, making it very likely that we captured only those withgreater than mild injury. Additionally, because patients with
congenital heart disease often have decreased muscle mass,
elevations in SCr may reflect more injury than in a healthy
opulation. Indeed, in a recent multicenter pooled analysis
f 2,322 critically ill children and adults with cardiorenal
yndrome, 20% of patients had early elevations in NGAL
ut never developed increases in SCr (28). Importantly, this
subgroup of NGAL-positive, SCr-negative subjects encoun-
tered a substantial increase in adverse outcomes, including
mortality, dialysis requirement, intensive care unit stay, and
prolonged hospital stay. Thus early biomarker measure-
ments may identify patients with subclinical AKI who have
an increased risk of adverse outcomes, even in the absence of
SCr rise.
Conclusions
This study is the first to demonstrate the temporal elevation
and progression of clinically relevant and predictive bio-
markers after AKI and the first to demonstrate the en-
hanced prediction of AKI using biomarker combinations.
The application of biomarker technology to create a bedside
AKI “panel” could allow clinicians the ability to pinpoint
timing of insult to the kidney and perhaps direct therapeutic
interventions. Results of this study support the inclusion of
urine NGAL, IL-18, L-FABP, and KIM-1 in such a panel.
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